Your session is about to expire
← Back to Search
Fremanezumab for Preventing Migraines
Study Summary
This trial is designed to see if the drug fremanezumab is effective in preventing migraines. It will last up to 36 months and will compare the drug to a placebo.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 4 trial • 353 Patients • NCT04041284Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have been taking the same medication for your migraines for the past two months.I was diagnosed with migraines over 6 months ago.I am applying for my child as their caregiver.I have experienced 8 migraines in the past month.I have had 15 headaches in the past month.
- Group 1: Fremanezumab
- Group 2: Placebo
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the United States Federal Drug Administration given their okay to Fremanezumab?
"There is supporting clinical data for Fremanezumab's efficacy and safety, so it received a score of 3."
How can I become a candidate for this research project?
"According to the eligibility requirements, candidates must suffer from migraines, be between 6 and 17 years old, and not have any other conflicting medical conditions. A total of 288 participants can enroll in the trial."
Are there other ongoing or completed investigations involving Fremanezumab?
"4 clinical trials for Fremanezumab are still live, with 3 of them in Phase 3. Most of these trials originated in Dresden, Illinois; however, there are now 241 active locations for these trials."
How many total individuals are taking part in this experiment?
"The clinical trial will require 288 participants that satisfy the pre-determined inclusion criteria. The sponsor, Teva Branded Pharmaceutical Products R&D, Inc., will manage the study from various locations, two of which are Teva Investigational Site 14365 in Baltimore, Maryland and Teva Investigational Site 14277 in Tacoma, Washington."
What is the precedent for this type of research?
"First studied in 2020, Fremanezumab is still being researched today by Teva Branded Pharmaceutical Products R&D, Inc. and others. There are 4 clinical trials currently underway across 9 countries and 44 cities."
Are there any positions still available for participants in this research?
"Yes, this information is correct. The study is still recruiting patients and the most recent update was on 8/23/2022."
Does this research study have an age limit?
"As this is a clinical trial for children and adolescents, only patients aged 6 to 17 are eligible to apply. Out of the 356 total clinical trials, 35 studies focus on this age group while 121 are for patients over 65 years old."
Are there different research facilities within the state that are conducting this investigation?
"There are a total of 35 medical centres enrolling patients in this trial, including Teva Investigational Site 14365 in Baltimore, Teva Investigational Site 14277 in Tacoma, and Teva Investigational Site 14325 in Miami."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
How responsive is this trial?
Typically responds via
Most responsive sites:
- Teva Investigational Site 14250: < 48 hours
Average response time
- < 2 Days
Share this study with friends
Copy Link
Messenger